RxDoctor Payments Data

Aaron Davidson, MD

Ophthalmology · Statesboro, GANPI 1790858991

Payments from drug & device makers

$626in general payments, 2019–2025

Across 9 payments — averaging $69.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$266
  • Atricure, Inc.$145
  • Johnson & Johnson$66
  • Amarin Pharma, Inc.$58
  • Actelion Pharmaceuticals US, Inc.$47
  • Alcon$26
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$60897%
  • Education$183%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$626 in reported general payments places this provider in the 25th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$97,167
Medicare patients
307
Services billed
3,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost72$36,428
RocklatanNetarsudil Mesylat/Latanoprost40$16,917
RhopressaNetarsudil Mesylate26$11,802
SimbrinzaBrinzolamide/Brimonidine Tart25$7,938
Travoprost46$7,129
VyzultaLatanoprostene Bunod20$6,249
Latanoprost445$6,244
Brimonidine Tartrate157$5,536
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$5,059
Timolol Maleate113$1,598
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat59$1,391
Doxycycline Hyclate53$1,347
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha102$1,334
Dorzolamide Hcl44$894
Prednisolone Acetate21$868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$26$7,93825 claims
Bausch & Lomb Americas Inc.Vyzulta$18$6,24920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Statesboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →